Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study

Michael Weichenthal; Eva Ellebaek

doi:10.1016/j.ejcskn.2026.101149

Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study

Michael Weichenthal^*, Eva Ellebaek

^*Corresponding author for this work

Original language	English
Article number	101149
Journal	EJC Skin Cancer
Volume	4
Number of pages	1
DOIs	https://doi.org/10.1016/j.ejcskn.2026.101149
Publication status	Published - 22 Jun 2026

Access to Document

10.1016/j.ejcskn.2026.101149Licence: CC BY-NC-ND

Cite this

Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study. / Weichenthal, Michael; Ellebaek, Eva.
In: EJC Skin Cancer, Vol. 4, 101149, 22.06.2026.

Research output: Contribution to journal › Comment/debate › Research › peer-review

@article{a38d56580b8b49d8ab5642d8272b0cd1,

title = "Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study",

author = "Michael Weichenthal and Eva Ellebaek",

year = "2026",

month = jun,

day = "22",

doi = "10.1016/j.ejcskn.2026.101149",

language = "English",

volume = "4",

journal = " EJC Skin Cancer",

issn = "2772-6118",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study

AU - Weichenthal, Michael

AU - Ellebaek, Eva

PY - 2026/6/22

Y1 - 2026/6/22

UR - https://www.scopus.com/pages/publications/105043227336

U2 - 10.1016/j.ejcskn.2026.101149

DO - 10.1016/j.ejcskn.2026.101149

M3 - Comment/debate

AN - SCOPUS:105043227336

SN - 2772-6118

VL - 4

JO - EJC Skin Cancer

JF - EJC Skin Cancer

M1 - 101149

ER -

Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study

Access to Document

Other files and links

Cite this